目次

TABLE OF CONTENTS

1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 STUDY SCOPE
1.3.1 MARKET SEGMENTATION & REGIONAL SCOPE
1.3.2 INCLUSIONS & EXCLUSIONS
1.3.3 YEARS CONSIDERED
1.4 CURRENCY CONSIDERED
1.5 MARKET STAKEHOLDERS
1.6 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA SOURCES
2.1.1 SECONDARY DATA
2.1.1.1 List of secondary sources
2.1.2 PRIMARY DATA SOURCES
2.1.2.1 List of key primary stakeholders interviewed
2.1.2.2 Insights from primary experts
2.2 MARKET ESTIMATION METHODOLOGY
2.2.1 APPROACH 1: COMPANY REVENUE ESTIMATION APPROACH
2.2.2 APPROACH 2: CUSTOMER-BASED MARKET ESTIMATION
2.3 MARKET FORECASTING
2.4 PRIMARY RESEARCH VALIDATION
2.5 DATA TRIANGULATION & MARKET BREAKDOWN
2.6 RESEARCH ASSUMPTIONS
2.6.1 STUDY ASSUMPTIONS
2.7 RESEARCH LIMITATIONS
2.8 RISK ASSESSMENT

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS
4.1 NEAR-INFRARED IMAGING MARKET OVERVIEW
4.2 EUROPE: NEAR-INFRARED IMAGING MARKET, BY PRODUCT AND COUNTRY (2024)
4.3 NEAR-INFRARED IMAGING MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
4.4 NEAR-INFRARED IMAGING MARKET: REGIONAL MIX, 2023-2030 (USD MILLION)

5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Increasing number of surgical procedures globally
5.2.1.2 Advantages of near-infrared imaging over conventional visualization methods
5.2.1.3 Technological advancements in near-infrared imaging modalities
5.2.1.4 Adoption of hybrid near-infrared imaging modalities for surgical guidance and molecular imaging
5.2.2 RESTRAINTS
5.2.2.1 Lengthy approval process of near-infrared fluorophores
5.2.2.2 High initial capital and operational costs of near-infrared systems
5.2.2.3 Availability of alternate technologies
5.2.3 OPPORTUNITIES
5.2.3.1 Growth potential for major players in emerging economies
5.2.3.2 Use of blockchain for distribution and storage of medical images
5.2.4 CHALLENGES
5.2.4.1 Hospital budget cuts
5.2.4.2 Dearth of trained professionals in emerging economies
5.3 REGULATORY ANALYSIS
5.3.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.3.2 REGULATORY LANDSCAPE
5.3.2.1 North America
5.3.2.1.1 US
5.3.2.1.2 Canada
5.3.2.2 Europe
5.3.2.3 Asia Pacific
5.3.2.3.1 Japan
5.3.2.3.2 China
5.3.2.3.3 India
5.3.2.4 Middle East (GCC Region)
5.3.2.4.1 UAE
5.3.2.4.2 Saudi Arabia
5.3.2.5 Africa
5.4 REIMBURSEMENT ANALYSIS
5.5 VALUE CHAIN ANALYSIS
5.5.1 RESEARCH & DEVELOPMENT
5.5.2 PROCUREMENT & PRODUCT DEVELOPMENT
5.5.3 MARKETING, SALES, AND DISTRIBUTION
5.6 SUPPLY CHAIN ANALYSIS
5.6.1 PROMINENT COMPANIES
5.6.2 SMALL & MEDIUM-SIZED ENTERPRISES
5.6.3 END USERS
5.7 ECOSYSTEM ANALYSIS
5.8 PORTER'S FIVE FORCES ANALYSIS
5.8.1 INTENSITY OF COMPETITIVE RIVALRY
5.8.2 BARGAINING POWER OF SUPPLIERS
5.8.3 BARGAINING POWER OF BUYERS
5.8.4 THREAT OF SUBSTITUTES
5.8.5 THREAT OF NEW ENTRANTS
5.9 KEY STAKEHOLDERS & BUYING CRITERIA
5.9.1 KEY STAKEHOLDERS IN BUYING PROCESS
5.9.2 KEY BUYING CRITERIA
5.10 TRADE ANALYSIS
5.10.1 IMPORT DATA FOR NEAR-INFRARED IMAGING PRODUCTS (HS CODE 902750)
5.10.2 EXPORT DATA FOR NEAR-INFRARED IMAGING PRODUCTS (HS CODE 902750)
5.11 PATENT ANALYSIS
5.12 PRICING ANALYSIS
5.12.1 AVERAGE SELLING PRICE OF NEAR-INFRARED IMAGING PRODUCTS, BY TYPE
5.12.2 AVERAGE SELLING PRICE OF NEAR-INFRARED IMAGING PRODUCTS, BY KEY PLAYER
5.12.3 AVERAGE SELLING PRICE OF NEAR-INFRARED IMAGING PRODUCTS, BY REGION
5.13 TECHNOLOGY ANALYSIS
5.13.1 KEY TECHNOLOGIES
5.13.1.1 InGaAs (Indium Gallium Arsenide) detectors
5.13.1.2 CMOS sensors
5.13.1.3 Hyperspectral imaging
5.13.2 COMPLEMENTARY TECHNOLOGIES
5.13.2.1 Image processing software
5.13.2.2 Optical coherence tomography (OCT)
5.13.2.3 Raman spectroscopy
5.13.3 ADJACENT TECHNOLOGIES
5.13.3.1 SWIR (short-wave infrared) imaging
5.13.3.2 Thermal imaging
5.13.3.3 UV-VIS-NIR spectroscopy
5.14 CASE STUDY ANALYSIS
5.14.1 TECHNOLOGICAL CHALLENGES
5.14.2 LOWERING DEPENDENCE ON CONTRACT MANUFACTURING
5.15 KEY CONFERENCES & EVENTS, 2025-2026
5.16 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
5.17 INVESTMENT & FUNDING SCENARIO
5.18 UNMET NEEDS ANALYSIS
5.19 IMPACT OF GENERATIVE AI ON NEAR-INFRARED IMAGING MARKET
5.20 IMPACT OF 2025 US TARIFFS ON NEAR-INFRARED IMAGING MARKET
5.20.1 KEY TARIFF RATES
5.20.2 PRICE IMPACT ANALYSIS
5.20.3 PRICE IMPACT ON COUNTRY/REGION
5.20.3.1 US
5.20.3.2 Europe
5.20.3.3 Asia Pacific
5.20.4 IMPACT ON COUNTRY/REGION
5.20.4.1 US
5.20.4.2 Europe
5.20.4.3 Asia Pacific
5.20.5 IMPACT ON END-USE INDUSTRIES

6 NEAR-INFRARED IMAGING MARKET, BY PRODUCT
6.1 INTRODUCTION
6.2 DEVICES
6.2.1 FLUORESCENCE IMAGING SYSTEMS
6.2.1.1 Higher sensitivity and better real-time image guidance during surgeries to drive market
6.2.2 FLUORESCENCE & BIOLUMINESCENCE IMAGING SYSTEMS
6.2.2.1 Better sensitivity and higher efficiency at lower costs to drive market
6.3 AGENTS/PROBES
6.3.1 INDOCYANINE GREEN
6.3.1.1 Increasing utilization of small organic probes in near-infrared imaging to drive segmental growth
6.3.2 OTHER REAGENTS
6.4 DYES
6.4.1 ORGANIC DYES
6.4.1.1 Unique molecular structure and better compatibility with biological systems to support market growth
6.4.2 NANOPARTICLE DYES
6.4.2.1 Better brightness and enhanced signal intensity compared to organic dyes to boost adoption

7 NEAR-INFRARED IMAGING MARKET, BY PROCEDURE
7.1 INTRODUCTION
7.2 CANCER SURGERIES
7.2.1 BRAIN CANCER/TUMOR SURGERIES
7.2.1.1 Advancements in surgical navigation using NIR-I/II fluorescence imaging to drive market growth
7.2.2 OTHER CANCER SURGERIES
7.3 GASTROINTESTINAL SURGERIES
7.3.1 COLORECTAL SURGERIES
7.3.1.1 Advancements in treatment strategies and procedures to support market growth
7.3.2 OTHER GASTROINTESTINAL SURGERIES
7.4 CARDIOVASCULAR SURGERIES
7.4.1 RISING PREVALENCE OF CARDIOVASCULAR DISEASES AMONG ALL AGE GROUPS TO DRIVE MARKET GROWTH
7.5 PLASTIC/RECONSTRUCTIVE SURGERIES
7.5.1 RISING NUMBER OF RECONSTRUCTIVE SURGERIES GLOBALLY TO BOOST MARKET
7.6 OBSTETRICS & GYNECOLOGY SURGERIES
7.6.1 INCREASED NUMBER OF CLINICAL TRIALS AND IMPROVED TISSUE CONTRAST DURING SURGERIES TO CONTRIBUTE TO GROWTH
7.7 OTHER PROCEDURES

8 NEAR-INFRARED IMAGING MARKET, BY APPLICATION
8.1 INTRODUCTION
8.2 PRECLINICAL IMAGING
8.2.1 GROWING FOCUS ON DEVELOPING NEW TREATMENTS FOR CHRONIC DISEASES TO DRIVE MARKET
8.3 CLINICAL IMAGING
8.3.1 INCREASING USE OF NEAR-INFRARED IMAGING FOR REAL-TIME VISUALIZATION DURING SURGERIES TO FUEL GROWTH
8.4 MEDICAL IMAGING
8.4.1 GROWING APPLICATIONS OF FLUORESCENCE IMAGING SINGLE-CELL TRACKING FOR STUDYING IMMUNE SYSTEM TO DRIVE MARKET

9 NEAR-INFRARED IMAGING MARKET, BY END USER
9.1 INTRODUCTION
9.2 HOSPITALS & SURGICAL CLINICS
9.2.1 RISING NUMBER OF CANCER AND RECONSTRUCTIVE SURGERIES TO DRIVE MARKET GROWTH
9.3 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
9.3.1 GROWING PRECLINICAL RESEARCH AND DRUG DISCOVERY TO BOOST GROWTH
9.4 RESEARCH LABORATORIES & ACADEMIC INSTITUTES
9.4.1 FUNDING FROM GOVERNMENT ORGANIZATIONS FOR BIOMEDICAL RESEARCH TO SUPPORT MARKET GROWTH
9.5 OTHER END USERS

10 NEAR-INFRARED IMAGING MARKET, BY REGION
10.1 INTRODUCTION
10.2 NORTH AMERICA
10.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
10.2.2 US
10.2.2.1 Advanced healthcare infrastructure and favorable regulations to drive market
10.2.3 CANADA
10.2.3.1 Increased availability of research funding to drive market
10.3 EUROPE
10.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
10.3.2 GERMANY
10.3.2.1 Increasing healthcare expenditure and government spending to drive market growth
10.3.3 FRANCE
10.3.3.1 Increasing target patient population and rising number of diagnostic tests for chronic diseases to boost market
10.3.4 UK
10.3.4.1 Growing government initiatives and increasing incidence of chronic diseases to support growth
10.3.5 ITALY
10.3.5.1 Increased availability of reimbursement coverage for diagnostic procedures to fuel growth
10.3.6 SPAIN
10.3.6.1 Increasing prevalence of cancer and growing private-public funding to propel growth
10.3.7 REST OF EUROPE
10.4 ASIA PACIFIC
10.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
10.4.2 CHINA
10.4.2.1 Increasing healthcare reforms and government investments to drive market
10.4.3 JAPAN
10.4.3.1 Fast adoption of advanced technologies and growth in geriatric population to boost market
10.4.4 INDIA
10.4.4.1 Increasing number of diagnostic procedures and improving healthcare infrastructure to drive market
10.4.5 AUSTRALIA
10.4.5.1 Growing healthcare spending and increasing investments in research to fuel growth
10.4.6 SOUTH KOREA
10.4.6.1 Presence of advanced healthcare system and increased awareness about diseases to contribute to growth
10.4.7 REST OF ASIA PACIFIC
10.5 LATIN AMERICA
10.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
10.5.2 BRAZIL
10.5.2.1 Greater purchasing power and more favorable demographic conditions to boost growth
10.5.3 MEXICO
10.5.3.1 Increased medical tourism and better government healthcare initiatives to drive market
10.5.4 REST OF LATIN AMERICA
10.6 MIDDLE EAST & AFRICA
10.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
10.6.2 GCC COUNTRIES
10.6.2.1 Supportive government initiatives to aid market growth
10.6.3 REST OF MIDDLE EAST & AFRICA

11 COMPETITIVE LANDSCAPE
11.1 OVERVIEW
11.2 KEY PLAYER STRATEGY/RIGHT TO WIN
11.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN NEAR-INFRARED IMAGING MARKET
11.3 REVENUE ANALYSIS, 2020-2024
11.4 MARKET SHARE ANALYSIS, 2024
11.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
11.5.1 STARS
11.5.2 EMERGING LEADERS
11.5.3 PERVASIVE PLAYERS
11.5.4 PARTICIPANTS
11.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
11.5.5.1 Company footprint
11.5.5.2 Region footprint
11.5.5.3 Product footprint
11.5.5.4 Procedure footprint
11.5.5.5 Application footprint
11.5.5.6 End-user footprint
11.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
11.6.1 PROGRESSIVE COMPANIES
11.6.2 RESPONSIVE COMPANIES
11.6.3 DYNAMIC COMPANIES
11.6.4 STARTING BLOCKS
11.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
11.6.5.1 Detailed list of key startups/SMEs
11.6.5.2 Competitive benchmarking of key emerging players/startups
11.7 COMPANY VALUATION & FINANCIAL METRICS
11.7.1 FINANCIAL METRICS
11.7.2 COMPANY VALUATION
11.8 BRAND/PRODUCT COMPARISON
11.9 COMPETITIVE SCENARIO
11.9.1 PRODUCT LAUNCHES
11.9.2 DEALS
11.9.3 EXPANSIONS

12 COMPANY PROFILES
12.1 KEY PLAYERS
12.1.1 STRYKER
12.1.1.1 Business overview
12.1.1.2 Products offered
12.1.1.3 Recent developments
12.1.1.3.1 Product launches
12.1.1.3.2 Deals
12.1.1.4 MnM view
12.1.1.4.1 Right to win
12.1.1.4.2 Strategic choices
12.1.1.4.3 Weaknesses & competitive threats
12.1.2 CARL ZEISS MEDITEC AG
12.1.2.1 Business overview
12.1.2.2 Products offered
12.1.2.3 Recent developments
12.1.2.3.1 Product launches
12.1.2.3.2 Deals
12.1.2.3.3 Expansions
12.1.2.4 MnM view
12.1.2.4.1 Right to win
12.1.2.4.2 Strategic choices
12.1.2.4.3 Weaknesses & competitive threats
12.1.3 PERKINELMER, INC.
12.1.3.1 Business overview
12.1.3.2 Products offered
12.1.3.3 Recent developments
12.1.3.3.1 Expansions
12.1.4 OLYMPUS CORPORATION
12.1.4.1 Business overview
12.1.4.2 Products offered
12.1.4.3 Recent developments
12.1.4.3.1 Product launches
12.1.4.3.2 Deals
12.1.4.3.3 Expansions
12.1.4.4 MnM view
12.1.4.4.1 Right to win
12.1.4.4.2 Strategic choices
12.1.4.4.3 Weaknesses & competitive threats
12.1.5 LEICA MICROSYSTEMS
12.1.5.1 Business overview
12.1.5.2 Products offered
12.1.5.3 Recent developments
12.1.5.3.1 Deals
12.1.5.3.2 Expansions
12.1.5.4 MnM view
12.1.5.4.1 Right to win
12.1.5.4.2 Strategic choices
12.1.5.4.3 Weaknesses & competitive threats
12.1.6 KARL STORZ SE & CO. KG
12.1.6.1 Business overview
12.1.6.2 Products offered
12.1.6.3 MnM view
12.1.6.3.1 Right to win
12.1.6.3.2 Strategic choices
12.1.6.3.3 Weaknesses & competitive threats
12.1.7 SHIMADZU CORPORATION
12.1.7.1 Business overview
12.1.7.2 Products offered
12.1.7.3 Recent developments
12.1.7.3.1 Product launches
12.1.7.3.2 Deals
12.1.7.3.3 Expansions
12.1.8 LI-COR BIOTECH, LLC
12.1.8.1 Business overview
12.1.8.2 Products offered
12.1.8.3 Recent developments
12.1.8.3.1 Product launches
12.1.9 HAMAMATSU PHOTONICS K.K.
12.1.9.1 Business overview
12.1.9.2 Products offered
12.1.9.3 Recent developments
12.1.9.3.1 Expansions
12.1.10 QUEST MEDICAL IMAGING B.V.
12.1.10.1 Business overview
12.1.10.2 Products offered
12.1.11 MERCK KGAA (SIGMA-ALDRICH)
12.1.11.1 Business overview
12.1.11.2 Products offered
12.1.11.3 Recent developments
12.1.11.3.1 Expansions
12.1.12 MIZUHO MEDICAL CO., LTD.
12.1.12.1 Business overview
12.1.12.2 Products offered
12.1.13 TELEDYNE PRINCETON INSTRUMENTS
12.1.13.1 Business overview
12.1.13.2 Products offered
12.1.14 THERMO FISHER SCIENTIFIC INC.
12.1.14.1 Business overview
12.1.14.2 Products offered
12.1.15 FLUOPTICS SAS (PART OF GETINGE)
12.1.15.1 Business overview
12.1.15.2 Products offered
12.1.16 MEDTRONIC
12.1.16.1 Business overview
12.1.16.2 Products offered
12.1.17 CAYMAN CHEMICAL
12.1.17.1 Business overview
12.1.17.2 Products offered
12.1.18 MP BIOMEDICALS
12.1.18.1 Business overview
12.1.18.2 Products offered
12.1.19 CRYSTA-LYN CHEMICAL COMPANY
12.1.19.1 Business overview
12.1.19.2 Products offered
12.1.20 GOWERLABS LTD.
12.1.20.1 Business overview
12.1.20.2 Products offered
12.2 OTHER PLAYERS
12.2.1 NIRX MEDICAL TECHNOLOGIES, LLC
12.2.2 EXOSENS (XENICS NV)
12.2.3 BIOTIUM
12.2.4 TOKYO CHEMICAL INDUSTRY (INDIA) PVT. LTD.
12.2.5 AAT BIOQUEST, INC.
12.2.6 OXFORD INSTRUMENTS
12.2.7 MOTHERSON
12.2.8 PHOTON ETC
12.2.9 SOTERIX MEDICAL INC.
12.2.10 KERNEL

13 APPENDIX
13.1 DISCUSSION GUIDE
13.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
13.3 CUSTOMIZATION OPTIONS
13.4 RELATED REPORTS
13.5 AUTHOR DETAILS